Eli Lilly's Ebglyss meets primary endpoints in Phase IIIb ADtouch trial for moderate-to-severe hand and foot atopic dermatitis. Label expansion expected.
CAS and Novartis collaborate on AI-ready reaction informatics for drug discovery. Access 160M+ curated reactions. Learn how ...
SCYNEXIS awarded $214M non-dilutive BARDA funding to advance SCY-247 antifungal candidate into Phase II trials for serious ...
Aptadir Therapeutics secures €40 million seed funding led by 4BIO Capital for RNA therapeutics targeting Fragile X Syndrome.
Immix Biopharma secures $125 million funding to advance NXC-201 CAR-T therapy for amyloidosis treatment. Learn about this ...
Merck (NYSE: MRK) has agreed to pay USD 400 million upfront to exclusively license SPR2015, a preclinical oral KRAS G12D-targeted RAS(ON) inhibitor from... Ortet, a new artificial intelligence lab ...
Bio secures $48M Series A funding to develop in vivo Th17 cell-targeting therapies for autoimmune diseases. Led by UPMC Enterprises and Ziff Capital.
Ortet, a new frontier AI health lab, launches with $500M from Thoreau to build patient-centered foundation models. Learn how ...
AstraZeneca submits NDA to FDA for savolitinib plus osimertinib combination therapy for MET-driven NSCLC. Learn about this ...
Novo Nordisk acquires exclusive rights to Hengrui's once-weekly oral GLP-1/GIP agonist HRS-1596 for $300M upfront. Pharma ...
AstraZeneca invests $2 billion in Summit Therapeutics to accelerate ivonescimab-ADC combination trials. Clinical ...
Arvinas doses first patient in Phase I/II trial of ARV-6723, an oral HPK1 PROTAC degrader for advanced solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results